ES2148116T1 - Metodos de detectar la enfermedad de alzheimer. - Google Patents

Metodos de detectar la enfermedad de alzheimer.

Info

Publication number
ES2148116T1
ES2148116T1 ES93923745T ES93923745T ES2148116T1 ES 2148116 T1 ES2148116 T1 ES 2148116T1 ES 93923745 T ES93923745 T ES 93923745T ES 93923745 T ES93923745 T ES 93923745T ES 2148116 T1 ES2148116 T1 ES 2148116T1
Authority
ES
Spain
Prior art keywords
disease
subject
methods
alzheimer
apoe4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES93923745T
Other languages
English (en)
Inventor
Allen D Roses
Warren J Strittmatter
Guy S Salvesen
Jan Enghild
Donald E Schmechel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26812201&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2148116(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke University filed Critical Duke University
Publication of ES2148116T1 publication Critical patent/ES2148116T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBEN METODOS PARA DIAGNOSTICAR O PRONOSTICAR LA ENFERMEDAD DE ALZHEIMER EN UN INDIVIDUO. EL METODO INCLUYE LA DETECCION DE LA PRESENCIA O AUSENCIA DE UNA APOLIPOPROTEINA E TIPO 4 (APOE4) O ADN CODIFICADOR DE APOE4 EN EL SUJETO. LA PRESENCIA DE APOE4 INDICA QUE EL SUJETO PADECE LA ENFERMEDAD DE ALZHEIMER O TIENE RIESGO DE DESARROLLARLA.
ES93923745T 1992-10-13 1993-09-30 Metodos de detectar la enfermedad de alzheimer. Pending ES2148116T1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95999292A 1992-10-13 1992-10-13
US11444893A 1993-08-31 1993-08-31

Publications (1)

Publication Number Publication Date
ES2148116T1 true ES2148116T1 (es) 2000-10-16

Family

ID=26812201

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923745T Pending ES2148116T1 (es) 1992-10-13 1993-09-30 Metodos de detectar la enfermedad de alzheimer.

Country Status (14)

Country Link
US (4) US5508167A (es)
EP (1) EP0625212B1 (es)
JP (1) JP3265577B2 (es)
KR (1) KR100279898B1 (es)
CN (2) CN1092525A (es)
AT (1) ATE262592T1 (es)
AU (1) AU677614B2 (es)
CA (1) CA2142300C (es)
DE (2) DE625212T1 (es)
ES (1) ES2148116T1 (es)
FI (1) FI951701A0 (es)
NO (1) NO951383D0 (es)
NZ (1) NZ257215A (es)
WO (1) WO1994009155A1 (es)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2148116T1 (es) * 1992-10-13 2000-10-16 Univ Duke Metodos de detectar la enfermedad de alzheimer.
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2716894B1 (fr) * 1994-03-07 1996-05-24 Pasteur Institut Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic.
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US7049078B2 (en) 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
GB9415073D0 (en) * 1994-06-27 1994-09-14 Smithkline Beecham Plc Novel method
GB9414624D0 (en) * 1994-07-20 1994-09-07 Smithkline Beecham Plc Novel method
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
FR2730745B1 (fr) * 1995-02-17 1997-06-13 Eurobio Lab Procede de detection d'une mutation intervenant dans la maladie d'alzheimer et sequences nucleotidiques pour sa mise en oeuvre
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5773220A (en) * 1995-07-28 1998-06-30 University Of Pittsburgh Determination of Alzheimer's disease risk using apolipoprotein E and .alpha.
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
US5672685A (en) * 1995-10-04 1997-09-30 Duke University Source of apolipoprotein E and method of isolating apolipoprotein E
WO1997016194A1 (en) * 1995-11-02 1997-05-09 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
US6136530A (en) * 1995-11-29 2000-10-24 Texas Tech University Health Sciences Center Compositions and methods for assessing risk factors in Alzheimer's disease
EP0785282A3 (en) 1996-01-19 1998-09-02 Washington University School Of Medicine Diagnosing and prognosing disease using sequences of the presenilin-1 gene
WO1998001101A2 (en) 1996-07-09 1998-01-15 Crutcher Keith A Methods for the treatment of apolipoprotein e related diseases
ES2115553B1 (es) * 1996-10-23 1999-02-16 Boehringer Ingelheim Espana Metodo para detectar la presencia de polimorfismos de dna, estuche de ensayo y acidos nucleicos recombinantes correspondientes.
AT404993B (de) * 1997-01-13 1999-04-26 Immuno Ag Verfahren zur bestimmung eines proteins mit einer mutation
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
US6313089B1 (en) * 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
US6342350B1 (en) 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
CA2297005A1 (en) * 1997-09-12 1999-03-25 Anthony David Smith Method for determining propensity for developing late-onset alzheimer's disease
ES2142248B1 (es) * 1997-11-20 2000-11-16 Univ Madrid Autonoma Polimorfismos en el promotor del gen humano de la apolipoproteina e, y sus usos para aplicaciones diagnosticas y terapeuticas.
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
AU3979099A (en) 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
US6441149B1 (en) 1998-06-15 2002-08-27 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6489095B2 (en) * 1998-06-15 2002-12-03 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6218117B1 (en) * 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
CA2354544A1 (en) * 1998-10-01 2000-04-13 Variagenics, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
DE19855469C2 (de) * 1998-12-01 2001-01-11 Michael Esrich Verfahren zur Bestimmung des Apolipoprotein-E-Genotyps in einer menschlichen Probe
US6017913A (en) * 1999-05-03 2000-01-25 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
EP1228240A2 (en) * 1999-05-07 2002-08-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Diagnosis of glaucoma
US20030068632A1 (en) * 1999-05-07 2003-04-10 Institute National De La Sante Et De La Recherche Medicale (Inserm) Diagnosis of glaucoma
US6255054B1 (en) 1999-09-09 2001-07-03 Jacques Hugon Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
US6432643B1 (en) * 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US6734166B1 (en) 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system
AU2001253054A1 (en) * 2000-03-29 2001-10-08 The J. David Gladstone Institutes Methods of treating cognitive decline disease conditions with androgens
EP1292294B1 (en) 2000-05-01 2009-03-18 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001264950A1 (en) * 2000-05-26 2001-12-11 Duke University Methods of screening for parkinson's disease
US20040053251A1 (en) * 2000-06-30 2004-03-18 Pericak-Vance Margaret A. Methods of screening for alzheimer's disease
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
AU2002237847A1 (en) * 2001-02-12 2002-08-28 Akzo Nobel N.V Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2003031971A1 (fr) * 2001-10-04 2003-04-17 Immuno-Biological Laboratories Co., Ltd. Reactif pour detecter un facteur de risque de la maladie d'alzheimer, necessaire de detection a cet effet, et procede de detection du facteur de risque de la maladie d'alzheimer au moyen de ce necessaire
US7070945B2 (en) * 2001-04-25 2006-07-04 Syn X Pharma, Inc. Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment
US6451547B1 (en) 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US20030170678A1 (en) * 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
US20030224380A1 (en) * 2001-10-25 2003-12-04 The General Hospital Corporation Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
WO2003054143A2 (en) * 2001-10-25 2003-07-03 Neurogenetics, Inc. Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
CA2466596A1 (en) * 2001-11-09 2003-06-05 University Of Zurich Cyp46 genotype determination for risk and treatment evaluation of alzheimer's disease
US20030119074A1 (en) * 2001-12-20 2003-06-26 George Jackowski Diagnosis and treatment of dementia utilizing thrombospondin
US20030224446A1 (en) * 2001-12-20 2003-12-04 Harry G. Jean Method of predicting cytokine response to tissue injury
US7579147B2 (en) * 2002-05-07 2009-08-25 Wake Forest University Health Sciences Mutations in the macrophage scavenger receptor 1 gene alter risk of prostate cancer, asthma, and cardiovascular disease
US20040014109A1 (en) * 2002-05-23 2004-01-22 Pericak-Vance Margaret A. Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
US20040005566A1 (en) * 2002-07-02 2004-01-08 Genelink, Inc. Kits and methods for assessing cardiovascular health
AU2003251962A1 (en) * 2002-07-08 2004-01-23 Duke University Screening for alzheimer's disease
ATE422671T1 (de) * 2002-07-30 2009-02-15 David Gladstone Inst Verfahren zur diagnose von morbus alzheimer
AU2003266967B2 (en) * 2002-08-07 2006-11-16 Novartis Ag Methods for the treatment of dementia based on Apo E genotype
US7432355B2 (en) * 2002-08-09 2008-10-07 The J. David Gladstone Institutes Apolipoprotein E stable folding intermediate and methods of use thereof
US20060246437A1 (en) * 2003-07-11 2006-11-02 Pericak-Vance Margaret A Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
US20050191652A1 (en) * 2003-11-03 2005-09-01 Vance Jeffery M. Identification of genetic forms of a gene that leads to high risk for parkinson disease
JP4675330B2 (ja) 2003-11-14 2011-04-20 デューク ユニバーシティ シャルコー・マリー・ツース病２ａ型の検出方法
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
EP1692520A2 (en) * 2003-11-19 2006-08-23 Satoris, Inc. Method for diagnosis, stratification and monitoring of alzheimer's disease
CN1890266B (zh) * 2003-11-28 2012-10-03 阿斯特拉曾尼卡有限公司 抗体
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
US20050277129A1 (en) * 2004-01-22 2005-12-15 Genaissance Pharmaceuticals APOE genetic markers associated with age of onset of Alzheimer's disease
WO2005072152A2 (en) * 2004-01-22 2005-08-11 Genaissance Pharmaceuticals, Inc. Apoc1 genetic markers associated with age of onset of alzheimer's disease
US7256003B2 (en) * 2004-07-13 2007-08-14 The Research Foundation For Mental Hygiene, Inc. Method for differentiation of Alzheimer's Disease into subgroups
US7790390B2 (en) * 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) * 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US20100292154A1 (en) * 2005-06-17 2010-11-18 The Brigham And Women's Hospital, Inc. Protein profile for osteoarthritis
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
EP1915144A4 (en) * 2005-06-20 2009-08-19 Accera Inc METHOD FOR REDUCING OXIDATIVE DAMAGE AND IMPROVING MITOCHONDRIA EFFICIENCY
US20070148661A1 (en) * 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
US20080262047A1 (en) * 2005-09-22 2008-10-23 Allen D Roses Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients
WO2007086980A2 (en) * 2005-11-10 2007-08-02 Duke University Methods of determining the risk of developing coronary artery disease
US20070166765A1 (en) * 2006-01-16 2007-07-19 Christian Rohlff Protein isoforms and uses thereof
EP2001293B9 (en) 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
EP2037948B1 (en) 2006-05-30 2016-04-13 Mayo Foundation For Medical Education And Research Detecting and treating dementia
EP2687223B1 (en) 2006-05-30 2017-07-12 Mayo Foundation For Medical Education And Research Detecting and treating dementia
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
DE102006056337A1 (de) * 2006-11-29 2008-06-05 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
BRPI0721697A2 (pt) 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
US20110212075A1 (en) 2007-06-25 2011-09-01 Siemens Aktiengesellschaft Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
ES2556537T3 (es) 2007-07-31 2016-01-18 Accera, Inc. Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
WO2009062152A1 (en) * 2007-11-09 2009-05-14 Washington University In St. Louis Methods for measuring the metabolism of cns derived biomolecules in vivo
US9125881B2 (en) * 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
JP5833922B2 (ja) 2008-08-12 2015-12-16 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
US20110177061A1 (en) 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
EP2459742B1 (en) 2009-07-29 2016-04-06 Pharnext New diagnostic tools for alzheimer disease
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
WO2011133583A1 (en) * 2010-04-19 2011-10-27 Functional Neuromodulation Inc. Deep brain stimulation of memory circuits in alzheimer's disease
KR20140017513A (ko) * 2010-12-02 2014-02-11 워싱톤 유니버시티 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법
WO2012085217A1 (en) 2010-12-22 2012-06-28 Universite De La Mediterranee (Aix-Marseille Ii) A diagnostic method for dementias
EP2665479B1 (en) 2011-01-10 2019-06-26 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
EP2681555B1 (en) 2011-02-25 2020-04-08 Benaroya Research Institute Detection of an allergic disorder
MX358474B (es) 2012-04-13 2018-08-21 Oasis Diagnostics Corp Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
WO2014160871A2 (en) 2013-03-27 2014-10-02 The General Hospital Corporation Methods and agents for treating alzheimer's disease
WO2015143447A2 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
CA2962969C (en) 2014-09-30 2023-03-21 Washington University Tau kinetic measurements
CN105606814B (zh) * 2014-11-20 2017-09-15 深圳市安群生物工程有限公司 检测人ApoE‑ε4蛋白的荧光免疫层析试纸及其制备方法
EP3294290A1 (en) * 2015-05-11 2018-03-21 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
WO2017044840A1 (en) 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
AU2018215678A1 (en) 2017-02-06 2019-08-22 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
KR102064060B1 (ko) * 2017-03-23 2020-02-11 서울대학교산학협력단 뇌의 베타 아밀로이드 축적 감별용 혈중 바이오마커
WO2019200342A1 (en) * 2018-04-12 2019-10-17 The J. David Gladstone Institutes Methods for treating apoe4/4-associated disorders
WO2020112802A1 (en) * 2018-11-28 2020-06-04 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
CN110006976B (zh) * 2019-05-14 2021-06-15 黄河科技学院 一种检测阿尔茨海默症标志物的电化学免疫传感器、其制备方法及应用
CN114938633A (zh) * 2020-01-07 2022-08-23 赛隆特拉有限公司 阿尔茨海默病的治疗
CN112540178B (zh) * 2020-08-06 2023-12-19 武汉天德生物科技有限公司 一种检测早期老年痴呆症的免疫组化试剂盒及其使用方法
CN112151113A (zh) * 2020-09-27 2020-12-29 类承斌 一种迟发性阿尔茨海默症关联基因变异的早期筛查方法
KR102561438B1 (ko) * 2020-11-04 2023-07-28 사회복지법인 삼성생명공익재단 뇌 아밀로이드 베타 축적 가능성을 예측하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772549A (en) * 1986-05-30 1988-09-20 Biotechnology Research Partners, Ltd. Polymorphisms related to lipid metabolism: ApoB, ApoCII, ApoE, ApoAIV
US5168045A (en) * 1989-08-18 1992-12-01 The Scripps Research Institute Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
US5177189A (en) * 1989-08-18 1993-01-05 The Scripps Research Institute Polypeptide analogs of Apolipoprotein E
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
US5297562A (en) * 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
US5272055A (en) * 1991-12-24 1993-12-21 The University Of Kentucky Research Foundation Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method
ES2148116T1 (es) * 1992-10-13 2000-10-16 Univ Duke Metodos de detectar la enfermedad de alzheimer.

Also Published As

Publication number Publication date
AU5350094A (en) 1994-05-09
EP0625212A4 (en) 1995-02-08
EP0625212A1 (en) 1994-11-23
US5716828A (en) 1998-02-10
US6027896A (en) 2000-02-22
NZ257215A (en) 1996-12-20
DE69333461D1 (de) 2004-04-29
JPH07502418A (ja) 1995-03-16
WO1994009155A1 (en) 1994-04-28
DE625212T1 (de) 2000-11-02
DE69333461T2 (de) 2005-03-24
CA2142300A1 (en) 1994-04-28
NO951383L (no) 1995-04-07
CN1525168A (zh) 2004-09-01
JP3265577B2 (ja) 2002-03-11
CA2142300C (en) 2005-08-23
US5767248A (en) 1998-06-16
AU677614B2 (en) 1997-05-01
EP0625212B1 (en) 2004-03-24
US5508167A (en) 1996-04-16
CN1092525A (zh) 1994-09-21
FI951701A (fi) 1995-04-10
NO951383D0 (no) 1995-04-07
KR100279898B1 (ko) 2001-04-02
ATE262592T1 (de) 2004-04-15
FI951701A0 (fi) 1995-04-10

Similar Documents

Publication Publication Date Title
ES2148116T1 (es) Metodos de detectar la enfermedad de alzheimer.
Hammad et al. Interaction of Apolipoprotein J-Amyloid β-Peptide Complex with Low Density Lipoprotein Receptor-related Protein-2/Megalin: A MECHANISM TO PREVENT PATHOLOGICAL ACCUMULATION OF AMYLOID β-PEPTIDE
Yasuda et al. β2-glycoprotein I deficiency:: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis
Kamboh et al. Genetic studies of human apolipoproteins. V. A novel rapid procedure to screen apolipoprotein E polymorphism
Yamamura et al. A new isoform of apolipoprotein E—apo E-5—associated with hyperlipidemia and atherosclerosis
NO980439L (no) Detektering av genetisk predisposisjon for periodontal sykdom
Horiguchi et al. Bordetella bronchiseptica dermonecrotizing toxin stimulates assembly of actin stress fibers and focal adhesions by modifying the small GTP-binding protein rho
NZ284412A (en) Apolipoprotein E polymorphism and treatment of Alzheimer's Disease
ES2051744T3 (es) Hibridomas y moleculas paratopicas monoclonales de la apolipoproteina a-i.
SE8603591L (sv) Detektering av erftlig hyperkolesterolemi
ES2166822T3 (es) Procedimientos de seleccion de la enfermedad de crohn usando alelos de microsatelites de tnf.
Roddier et al. Two mutations in the HSN2 gene explain the high prevalence of HSAN2 in French Canadians
Nozaki et al. Homozygosity mapping to chromosome 5p15 of a gene responsible for Hartnup disorder
AU6823600A (en) Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease
ATE408708T1 (de) Mutationen in verbindung mit eisenerkrankungen
Børresen et al. The apoE polymorphism studied by two‐dimensional, high‐resolution gel electrophoresis of serum
Sanders et al. alpha 1 Antitrypsin (PI) allotypes in rheumatoid arthritis.
NO985280L (no) Anvendelse av en mutasjon i genet for human G-protein <beta>3 subenhet for diagnostisering av sykdommer
NO20002176D0 (no) Diagnostikk og terapi av kronisk obstruktiv luftveissykdom
Kouvonen et al. The role of sialic acid in the binding of calcium ions to intrinsic factor and its intestinal receptor
Sprecher et al. Identification of an apoC-II variant (apoC-IIBethesda) in a kindred with apoC-II deficiency and type I hyperlipoproteinemia.
Utsumi et al. Western blotting analysis of the β‐hexosaminidase α‐and β‐subunits in cultured fibroblasts from cases of various forms of GM2 gangliosidosis
Bárány et al. Evidence for isoforms of the phosphorylatable myosin light chain in rat uterus
Kondo et al. Inherited quantitative DNA variation in the LPA (“apolipoprotein (a)”) gene
Harrison et al. High‐resolution two‐dimensional electrophoretic survey of serum protein genetic types in Schmiedeleut Hutterites